Chemoressa 250mg Tablet 10’S

INTRODUCTION

CHEMORESSA 250MG contains gefitinib which belongs to a class of medicines called kinase inhibitors. It blocks a protein called ‘epidermal growth factor receptor’ (EGFR). This protein is involved in growth and spread of the cancer cells. It is used to treat with non-small cell lung cancer. This cancer is a disease in which the malignant (cancer) cells form in tissues of the lung.

Gefitinib acts by inhibiting ‘epidermal growth factor receptor’ (EGFR) signal transduction pathways. EGFR is found on the surface of many cancer as well as normal cells which receives signal from other cells and transmits it into the cell by causing a chemical reaction that modifies other proteins. By blocking these signals, it inhibits the growth and multiplication of the cells.

The recommended dose is 250 mg per day or as directed by physician. You can take with or without food. Do not take antacids for 2 hours before or 1 hour after taking CHEMORESSA 250MG. It is not indicated in the children and adolescents under 18 years. Tell your doctor if you are taking, have taken or might take any other medicines. Talk to your doctor before taking this medicine if you are pregnant, may become pregnant or breast-feeding. If you feel weak while taking this medicine, take care when driving or using tools or machines. The common side effects are diarrhea, vomiting, nausea, loss of appetite, weakness, red or sore mouth and dry mouth.

USES OF CHEMORESSA 250MG

• Treat adults with the non-small cell lung cancer

HOW CHEMORESSA 250MG WORKS

CHEMORESSA 250MG acts by inhibiting ‘epidermal growth factor receptor’ (EGFR) signal transduction pathways. EGFR is found on the surface of many cancer as well as normal cells which receives signal from other cells and transmits it into the cell by causing a chemical reaction that modifies other proteins. By blocking these signals, it inhibits the growth and multiplication of the cells.

DIRECTIONS FOR USE

The recommended dose is 250 mg per day or as directed by physician. You can take with or without food.

SIDE EFFECTS OF CHEMORESSA 250MG

HOW TO MANAGE SIDE EFFECTS

Skin Itching:

Avoid bath in hot water because hot water can irritate the skin. Moisturizers can be used regular basis to soothe and hydrate the affected area.

Nausea and vomiting:

Keep try taking this medicine with, or just after, a meal or snack and stick to simple meals and do not eat rich or spicy food.

Headache:

Apply hot or cold-water bag on your head. Take rest in a quiet and dark room. Drink tea or coffee.

Diarrhea:

Drink lot of fluid, such as water or squash, to avoid dehydration. Do not take any other medicine without consulting your doctor.

WARNING & PRECAUTIONS

INTERACTIONS

Talk to your doctor if you are taking:

• Phenytoin or carbamazepine (for epilepsy)
• Rifampicin (for tuberculosis)
• Itraconazole (for fungal infections)
• Barbiturates (medicine used for sleeping problems)
• Herbal remedies containing St John’s wort (Hypericum perforatum, used for the depression and anxiety)
• Proton-pump inhibitors, H2-antagonists and antacids

SYNOPSIS

MORE INFORMATION

Store below 20-25°C and keep out of reach of children.

FAQs ABOUT CHEMORESSA 250MG

How do I take CHEMORESSA 250MG?

Take this medicine with or without food as directed by your doctor, usually once daily.

How CHEMORESSA 250MG works?

It works by inhibiting the ‘epidermal growth factor receptor’ (EGFR) signal transduction pathways. EGFR is found on the surface of many cancer as well as normal cells which receives signal from other cells and transmits it into the cell by causing a chemical reaction that modifies other proteins. By blocking these signals, it inhibits the growth and multiplication of the cells.

Is CHEMORESSA 250MG cytotoxic?

No, it is not a cytotoxic agent.

REFERENCES

1. Fariz Nurwidya, Fumiyuki Takahashi and Kazuhisa Takahashi, Gefitinib in the treatment of non-small cell lung cancer with activating epidermal growth factor receptor mutation, [Approved on 2016] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934098/

2. M Tiseo, M Bartolotti, F Gelsomino, and P Bordi; Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC), [Published on 2010] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880339/

3. K.D.Tripathi, Essentials of medical pharmacology, Anticancer drugs, Chapter 62 – Chemotherapy of neoplastic disease, Page – 870.

4. AstraZeneca UK Limited; Electronic Medicines Compendium (EMC); [Revised on 02/2019] [Accessed 11 Nov 2020] https://www.medicines.org.uk/emc/files/pil.6602.pdf